George Coukos appointed director of new Ludwig Laboratory for Cell Therapy
2026-02-03
(Press-News.org) FEBRUARY 2, 2026, NEW YORK – It is with great pleasure that we announce that the Ludwig Institute for Cancer Research has established the Ludwig Laboratory for Cell Therapy at Weill Cornell Medicine’s Sandra and Edward Meyer Cancer Center. The laboratory is directed by former Ludwig Lausanne Director George Coukos, a physician-scientist and global authority on tumor immunology and cellular immunotherapy.
Coukos returns to the U.S. following an extraordinarily productive tenure over the past decade as the founding director of the current Lausanne Branch and of the Department of Oncology UNIL and CHUV. In these roles, he made several landmark discoveries in tumor immunology and established an ambitious bench-to-bedside research program for the development, production and clinical evaluation of cellular immunotherapies and cancer vaccines. During this time, he also recruited an exceptional, internationally recognized team of investigators, building the Lausanne Branch into a hub of scientific and translational excellence. Several technologies developed under his leadership—and with his direct participation—are now being applied in pioneering studies to optimize individualized cell therapies for the treatment of melanoma, sarcoma, lung cancer and other major malignancies.
Cellular immunotherapies involve the isolation from patients of tumor-targeting immune cells, their expansion in the lab and subsequent reintroduction to the same patients for cancer therapy. An intervening step often involves the selection and—mainly in currently experimental strategies—reengineering of the cells to better target the molecular features unique to a patient’s cancer, enhance their cancer-killing capabilities and equip them to better overcome the defenses tumors evolve against immune attack. Coukos has contributed invaluably to not only identifying mechanisms of immune evasion employed by tumors and markers of anti-tumor immunity but also to the translational strategies employed to optimize cellular immunotherapies.
“Few scientists are as qualified as George to lead a program on cellular immunotherapy, and fewer still can lay claim to the experience and grit required to get such a program off the ground and usher its discoveries into the clinic,” said Ludwig Institute CEO and Scientific Director Chi Van Dang. “We have every confidence that the new Ludwig Laboratory for Cell Therapy at Weill Cornell Medicine will thrive in his capable hands, leading to the establishment of an impactful translational and clinical cell therapy program. Further, George and his team will enjoy ready access to the world-class expertise nearby. He has abundant opportunities to leverage the remarkably innovative research on cancer immunotherapy at the Ludwig Collaborative Laboratory at Weill Cornell. In addition, George will have access to expertise in cancer and immune metabolism at the Princeton Branch of the Ludwig Institute. The Branch is affiliated with the Rutgers Cancer Institute, which has an established cell therapy research program.”
Ludwig Distinguished Scholar Douglas Hanahan will serve as interim director of Ludwig Lausanne until a permanent director is appointed to lead the Branch.
# # #
About Ludwig Cancer Research
Ludwig Cancer Research is an international collaborative network of acclaimed scientists that has pioneered cancer research and landmark discovery for more than 50 years. Ludwig combines basic science with the translation and clinical evaluation of its discoveries to accelerate the development of new cancer diagnostics, therapies and prevention strategies. Since 1971, Ludwig has invested nearly $3 billion in life-changing science through the not-for-profit Ludwig Institute for Cancer Research and the six U.S.-based Ludwig Centers. To learn more, visit www.ludwigcancerresearch.org.
For additional information please contact communications@ludwigcancerresearch.org.
About Weill Cornell Medicine
Weill Cornell Medicine is committed to excellence in patient care, scientific discovery and the education of future physicians in New York City and around the world. The doctors and scientists of Weill Cornell Medicine — faculty from Weill Cornell Medical College, Weill Cornell Graduate School of Medical Sciences, and Weill Cornell Physician Organization — are engaged in world-class clinical care and cutting-edge research that connect patients to the latest treatment innovations and prevention strategies. For more information, visit weill.cornell.edu
END
ELSE PRESS RELEASES FROM THIS DATE:
2026-02-03
WASHINGTON—A new expert opinion from the Society for Cardiovascular Angiography & Interventions (SCAI) examines the evolving role of angiography-derived physiology (ADP), a wire-free method for coronary physiologic assessment that applies computational modeling or artificial intelligence (AI) to standard coronary angiographic images for the assessment and management of coronary artery disease.
Published in JSCAI, “Angiography-Derived Physiology for Coronary Artery Disease Assessment: Expert Opinion from ...
2026-02-03
Young men are being encouraged to undergo testosterone testing and start hormone therapy through Instagram and TikTok content that promotes unproven health claims while downplaying medical risks, a new international study has found.
The study was done at the University of Sydney’s Faculty of Medicine and Health, and led by Emma Grundtvig Gram, a visiting PhD student from the University of Copenhagen. It found that influencer marketing on social media is normalising unnecessary testosterone testing ...
2026-02-03
In a new partnership between open-access scholarly publisher Pensoft and the AI-driven reviewer discovery system provider Prophy, the editorial teams at all journals hosted on the publisher’s ARPHA Platform receive access to a broader and more diverse global pool of researchers.
The integration connects ARPHA’s editorial and peer review workflows with Prophy’s continuously updated database of millions of active, qualified researchers. As a result, editorial teams across more than 90 open-access peer-reviewed journals powered by ARPHA can now opt to enjoy data-driven reviewer recommendations based on structured analysis ...
2026-02-03
WASHINGTON, Feb. 3, 2026 — Arctic sea ice has large effects on the global climate. By cooling the planet, Arctic ice impacts ocean circulation, atmospheric patterns, and extreme weather conditions, even outside the Arctic region. However, climate change has led to its rapid decline, and being able to make real-time predictions of sea ice extent (SIE) — the area of water with a minimum concentration of sea ice — has become crucial for monitoring sea ice health.
In Chaos, by AIP Publishing, researchers from the United States and the ...
2026-02-03
WASHINGTON, Feb. 3, 2026 — Kemp’s ridley sea turtles are among the most endangered species of sea turtles in the world. They reside along the east and Gulf coasts of North America, alongside some of the world’s most active shipping lanes. While the threats from fishing, pollution, and vessel collisions are well understood, it is less clear how disruptive human-caused noise is to their survival.
In JASA, published on behalf of the Acoustical Society of America by AIP Publishing, researchers from Duke University Marine Laboratory, the National Oceanic and Atmospheric Administration, and North Carolina State University evaluated ...
2026-02-03
About The Study: This multicenter, case-control study found that the vaccine effectiveness of 2024-2025 COVID-19 vaccines was associated with protection against COVID-19 hospitalization and severe in-hospital outcomes and against multiple JN.1 descendants. Monitoring COVID-19 vaccine effectiveness, including stratifying by SARS-CoV-2 lineage and spike protein mutations, remains important to guide COVID-19 vaccine composition and recommendations.
Corresponding Author: To contact the corresponding author, Kevin C. Ma, PhD, email tra3@cdc.gov.
To ...
2026-02-03
About The Study: This study demonstrated that respiratory syncytial virus (RSV), similar to influenza and SARSCoV-2, was associated with an increased risk of cardiorespiratory events 2 weeks following RSV-related hospitalization, and some conditions had significant risk elevations up to 180 days after admission. The findings reinforce the need to increase RSV immunization in adults.
Corresponding Author: To contact the corresponding author, Caihua Liang, MD, PhD, email caihua.liang@pfizer.com.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2025.56767)
Editor’s ...
2026-02-03
About The Study: In this cohort study, state-level abortion bans following Dobbs were associated with a disproportionate increase in the risk of postpartum depression among women and adolescents in low- socioeconomic status communities. These findings underscore the need for targeted mental health support and policy interventions to mitigate the unequal burden of such legislation on vulnerable populations.
Corresponding Author: To contact the corresponding author, Onur Baser, MA, MS, PhD, email onur.baser@sph.cuny.edu.
To access the embargoed study: ...
2026-02-03
A new study published in the Strategic Management Journal challenges long-standing assumptions about managerial specialization by examining when organizations perform better by having leaders collectively pursue multiple objectives rather than dividing responsibilities among them. Addressing the growing complexity of modern organizations—where financial, social, environmental, and technological goals increasingly coexist—the research introduces what the authors call the “common purpose advantage.”
Drawing on a computational model of multi-manager firms, the study compares performance under two approaches: “objective ...
2026-02-03
SAN ANTONIO — February 3, 2026 — Dr. Barron Bichon has been promoted to vice president of SwRI’s Mechanical Engineering Division. He previously served as the director of SwRI’s Materials Engineering Department. As vice president, Bichon will lead more than 400 staff members performing research, development, testing and evaluation for a wide variety of projects.
“I’m excited for the opportunity to lead our division as it continues to dedicate itself to innovation, collaboration and real-world impact,” Bichon said. “Leading this incredible team is ...
LAST 30 PRESS RELEASES:
[Press-News.org] George Coukos appointed director of new Ludwig Laboratory for Cell Therapy
